AstraZeneca’s (LSE: AZN) Koselugo (selumetinib) has been granted conditional approval in the European Union (EU) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in pediatric patients with neurofibromatosis type 1 (NF1) aged three years and above.
This follows a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human US (CHMP) in April this year. Under development with US pharma giant Merck & Co (NYSE: MRK), Koselugo gained US approval in April last year.
By 2026, data and analytics firm GlobalData forecasts total annual revenue of $206 million for Koselugo.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze